Search

Saprisartan

Saprisartan is an AT1 receptor antagonist. It is based on medications of losartan's prototypical chemical structure.

Nelarabine

[A2331,AA2334,A2335] Results from 2 phase 2 studies on adult and pediatric T-ALL/T-LBL indicated that nelarabine can yield a 13% complete response (CR) rate in pediatric patients and 18% in adult patients … ), in both adult and pediatric patients whose disease has not responded to or has relapsed following at least two chemotherapy regimens.

XEN-2174

XEN-2174 is a synthetic drug modeled on a peptide from the venom of a cone shell found on Australia's Great Barrier Reef. … NET is the primary mechanism regulating the biological effects of norepinephrine (NE) on the body.

Suprofen

An ibuprofen-type anti-inflammatory analgesic and antipyretic. It inhibits prostaglandin synthesis and has been proposed as an anti-arthritic. It is no longer approved for use in the United States.

Glycol salicylate

It is found as an active ingredient and topical analgesic in patches used to provide relief for mild to moderate muscle and joint pain [L2686]. … This ingredient is an important component of many topical creams and sprays for the relief of aches, pains, and stiffness of the muscles, joints, and tendons [L2696].

Marstacimab

[A264608] Marstacimab is used to prevent bleeding episodes in patients with hemophilia,[L51803] which is an X‐linked bleeding disorder characterized by coagulation clotting factor deficiency. … [L51803] It is a tissue factor pathway inhibitor (TFPI) antagonist, which is an endogenous anticoagulant.

Prazosin

Prazosin is marketed by _Pfizer_ and was initially approved by the FDA in 1988.[L5828] It belongs to the class of drugs known as alpha-1 antagonists. … Recently, many studies have evaluated the benefits of this drug in controlling the symptoms of post-traumatic stress disorder (PTSD) and associated nightmares.[A176618, A176621, A176624]

Kojic acid

Guanadrel

Guanadrel is an antihypertensive agent and postganglionic adrenergic blocking agent.

Agalsidase alfa

[A220228,A220233] Use of agalsidase beta has decreased in Europe, in favor of agalsidase alfa, after a contamination event in 2009. … [A220343] Agalsidase alfa was granted EMA approval on 3 August 2001.[L16413]